MedTrace Logo

ORAL T-8 Oral Testosterone for Male Hormonal Contraception

NCT01167829 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2013-09-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to test how the body absorbs a new form of oral testosterone (T). On Day 1 and Day 9 there are overnight stays in the General Clinical Research Center at the University of Washington to monitor blood testosterone levels over a 24-hour period.

Conditions

  • Healthy

Interventions

DRUG

Oral Testosterone

Oral Testosterone: 300 mg, pills, three times daily Day 1 - 10 (total of 27 pills)

DRUG

Acyline

300 ug/kg injection on Day 0

Sponsors & Collaborators

Principal Investigators

  • John K Amory, MD · University of Washington

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2010-10-31
Completion
2012-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01167829 on ClinicalTrials.gov